In a telling example of the growing importance of the gastrointestinal (GI) market, the main quibbles in last week's Arthritis Advisory Committee (adcom) meeting to discuss the application for CT-P13 (infliximab) – Celltrion Inc.'s biosimilar to Remicade (infliximab, Janssen Biotech Inc.) – focused more on the FDA's willingness to extrapolate clinical findings in rheumatoid arthritis and ankylosing spondylitis to inflammatory bowel disease (IBD) and related GI conditions than to the indications supported by clinical studies.